One Biotech CEO's Plan To Slash The Cost Of Cancer Immunotherapy

New immune-boosting drugs like Merck ’s Keytruda and Bristol-Myers Squibb BMY +1.61%’s Opdivo are changing the game for cancer patients, but their six-figure-per-year price tags have raised eyebrows among payers worldwide. Those cost concerns are top-of-mind for Ali Fattaey, a microbiologist and CEO of Massachusetts-based biotech company Curis, which has ventured into the world of immuno-oncology with a plan to make next generation of cancer drugs more affordable.

Hey, check out all the research scientist jobs. Post your resume today!